Abcellera Biologics
ABCL · NASDAQ
$11.71−$0.22 (−1.84%)TodayMarket closed ·
Prev close $11.93
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 43.0% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$0.18
- Revenue estimate
- $6.08M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.1457 | -$0.18 | −23.5% |
| Q1 FY26 | -$0.1996 | -$0.14 | +29.9% |
| Q4 FY25 | -$0.1775 | -$0.03 | +83.1% |
| Q3 FY25 | -$0.1721 | -$0.19 | −10.4% |
| Q2 FY25 | -$0.1693 | -$0.12 | +29.1% |
| Q1 FY25 | -$0.1448 | -$0.15 | −3.6% |
| Q4 FY24 | -$0.1568 | -$0.11 | +29.8% |
| Q3 FY24 | -$0.1547 | -$0.17 | −9.9% |
Earnings calls
- 12th Annual Cantor Fitzgerald Global Healthcare Conference
- Special Call - AbCellera Biologics Inc.
- ABCL - Earnings call Q2 2026
- Jefferies Global Healthcare Conference 2026
- Bank of America Global Healthcare Conference 2026
- ABCL - Earnings call Q1 2026
- 2026 KeyBanc Capital Markets Healthcare Virtual Forum
- TD Cowen 46th Annual Health Care Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.